Yeonhee Kim

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

Medicine, Oncology, Pharmacology +13

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown et al. · The Lancet Oncology · 2017 · 247 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan O’Brien, Nicole Lamanna, Thomas J. Kipps et al. · Blood · 2015 · 240 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +9

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon et al. · Blood · 2023 · 171 citations · Full text

Medicine, Oncology, Hematologic Oncology +11

The Catalytic Alkylation of Aromatic Imines by Wilkinson's Complex: The Domino Reaction of Hydroacylation andortho-Alkylation

Chul‐Ho Jun, Jun‐Bae Hong, Yeonhee Kim et al. · Angewandte Chemie International Edition · 2000 · 168 citations

Natural Sciences, Chemistry, Catalysis +8